Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KL 1333 (Primary) ; Bupropion; Caffeine; Dextromethorphan; Flurbiprofen; Midazolam; Omeprazole; Repaglinide
  • Indications Diabetes mellitus; Mitochondrial disorders
  • Focus Pharmacokinetics
  • Sponsors Abliva

    • Most Recent Events

    • 19 Oct 2021 Status changed from recruiting to completed.
    • 03 Dec 2020 New trial record
    • 20 Nov 2020 According to an Abliva media release, company doses the first healthy volunteers in the company's drug-drug interaction study (DDI study) with KL1333.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top